SHANGHAI and GUANGZHOU, China

中国上海和广州

,

，

July 4, 2026

2026年7月4日

/PRNewswire/ -- Sanyou Biopharmaceutical Co., Ltd. ('Sanyou Bio') and Guangzhou Baiyunshan Xihe Health Pharmaceutical Co., Ltd. ('Baiyunshan Xihe') jointly announced the official signing of a strategic cooperation agreement. This partnership will focus on the co-development of novel radiopharmaceuticals and radiodiagnostic products, aiming to integrate their respective core strengths in AI-driven innovative drug molecule discovery and the full industrial value chain of nuclear medicine.

/美通社/ -- 三友生物制药有限公司（“三友生物”）与广州白云山熙河健康药业有限公司（“白云山熙河”）联合宣布正式签署战略合作协议。此次合作将聚焦于新型放射性药物及放射诊断产品的共同开发，旨在整合双方在人工智能驱动的创新药物分子发现以及核医学全产业链价值方面的核心优势。

Together, the two parties seek to build an end-to-end innovation chain spanning from target molecule discovery to clinical translation of radiopharmaceuticals, delivering more transformative solutions for precision oncology diagnosis and therapy..

双方携手打造从靶点分子发现到放射性药物临床转化的端到端创新链，为精准肿瘤诊断与治疗提供更具变革性的解决方案。

The development of radiopharmaceuticals and radiodiagnostic products places extremely high demands on the precision, stability, and druggability of targeting molecules. This strategic collaboration is based on both parties' deep insight into the nuclear medicine industry trends and strong mutual recognition of each other's technological capabilities..

放射性药物和放射诊断产品的开发对靶向分子的精确性、稳定性和成药性提出了极高的要求。此次战略合作基于双方对核医学行业趋势的深刻洞察，以及对彼此技术实力的高度认可。

Sanyou Bio will leverage its globally leading AI-Super trillion antibody/molecule libraries (AI-STAL) and its Sanyou AI-Drug Accelerator (SAI-DA) to provide source innovation power for the discovery and optimization of high-performance antibodies and targeting molecules against specific targets. Baiyunshan Xihe will rely on its end-to-end capabilities in novel medical radionuclide production, GMP manufacturing, and clinical translation to advance partnered molecules into radiolabeling, in vitro and in vivo evaluation, and preclinical studies, thereby accelerating the industrialization of innovative radiopharmaceuticals and radiodiagnostic products..

三友生物将凭借其全球领先的AI超级万亿抗体/分子库（AI-STAL）和三友AI药物加速器（SAI-DA），为针对特定靶点的高性能抗体和靶向分子的发现与优化提供源头创新动力。白云山熙河将依托其在新型医用放射性核素生产、GMP制造及临床转化方面的端到端能力，推进合作分子进入放射性标记、体外和体内评估以及临床前研究阶段，从而加速创新放射性药物和放射诊断产品的产业化进程。

This strategic partnership aims to generate core value through deep integration across multiple dimensions:

该战略伙伴关系旨在通过多维度的深度融合创造核心价值：

1. Building an End-to-End Innovation Closed Loop:

1. 构建端到端的创新闭环：

Establish an integrated collaborative R&D model of 'AI-driven molecular discovery – radionuclide labeling – clinical translation,' seamlessly connecting upstream molecular discovery capabilities with the radiopharmaceutical industrialization platform, significantly shortening the development timeline from target concept to radiopharmaceutical candidate compounds..

建立“人工智能驱动的分子发现–放射性核素标记–临床转化”一体化协同研发模式，将上游分子发现能力与放射性药物产业化平台无缝衔接，显著缩短从靶点概念到放射性药物候选化合物的开发周期。

2. Developing a Differentiated Product Portfolio:

2. 开发差异化产品组合：

By combining Sanyou Bio's extensive experience in innovative drug development and its strengths in AI-driven molecular discovery with Baiyunshan Xihe's standardized production technologies for key medical radionuclides such as Gallium-68, Zirconium-89, Copper-64, and Rhenium-186, the two parties will jointly develop internationally competitive theranostic radiopharmaceuticals and novel radiodiagnostic products..

通过结合三友生物在创新药物开发方面的丰富经验及其在人工智能驱动分子发现领域的优势，以及白云山溪和在镓-68、锆-89、铜-64和铼-186等关键医用放射性核素标准化生产技术方面的专长，双方将共同开发具有国际竞争力的诊疗一体化放射性药物及新型放射性诊断产品。

3. Building a New Industrial Ecosystem for Collaboration:

3. 构建协同创新的新型产业生态：

Both parties will integrate their deep resources in innovative drug R&D services and the nuclear medicine industry chain, jointly explore open and mutually beneficial collaboration models, enhance China's upstream innovation capabilities in radiopharmaceuticals, and promote high-quality industry development..

双方将整合在创新药研发服务及核医学产业链方面的深厚资源，共同探索开放共赢的合作模式，提升中国在放射性药物领域的上游创新能力，推动行业高质量发展。

Liu Hong, Chairman and General Manager of Baiyunshan Xihe, stated:

白云山西河董事长兼总经理刘红表示：

'We are very pleased to enter into this strategic collaboration with Sanyou Bio. As a leading enterprise in Guangzhou's nuclear medicine industry chain, Baiyunshan Xihe has established a fully integrated value chain from radionuclide production to clinical services, and has developed a dual-track product portfolio featuring both self-developed nanobody-based RDCs and mature microsphere products.

“我们非常高兴与三友生物达成此次战略合作。作为广州核医学产业链的领军企业，白云山熙和已建立起从放射性核素生产到临床服务的全产业链价值体系，并形成了以自主研发的纳米抗体RDC药物和成熟的微球产品为核心的双轨产品组合。”

Sanyou Bio's AI-STAL platform for upstream drug discovery is globally leading, with a library capacity exceeding 11 trillion and outstanding screening capabilities. This collaboration will strongly complement our capabilities in targeting molecule discovery and accelerate the layout and advancement of our theranostic radiopharmaceutical pipeline.

三友生物的AI-STAL平台在药物发现上游领域处于全球领先地位，其库容量超过11万亿，并具备卓越的筛选能力。此次合作将有力补充我们在靶向分子发现方面的能力，加速我们诊疗一体化放射性药物管线的布局与推进。

We look forward to this deep integration of 'discovery + translation' to jointly develop truly clinically valuable innovative radiopharmaceutical products.'.

我们期待这种“发现+转化”的深度融合，以共同开发真正具有临床价值的创新型放射性药物产品。

Dr. Lang Guojun, Founder and CEO of Sanyou Bio, stated:

三友生物创始人兼首席执行官郎国军博士表示：

'This collaboration with Baiyunshan Xihe represents an important extension of Sanyou Bio's mission—'To make it easy to develop new drugs worldwide'—into the cutting-edge field of nuclear medicine. Backed by the strong industrial resources of Guangzhou Pharmaceutical Holdings, Baiyunshan Xihe has built solid capabilities in radionuclide production and full value-chain integration.

此次与白云山熙和的合作，标志着三友生物将其“让全球新药研发更简单”的使命重要地延伸至核医学前沿领域。依托广药集团的强大产业资源，白云山熙和在放射性核素生产及全产业链整合方面已建立起坚实的能力。

This strategic synergy is a key step in deeply connecting our AI-driven molecular discovery capabilities with a leading radiopharmaceutical industrialization platform. We believe that, through the dual engines of 'intelligent molecular design' and 'precise radionuclide labeling,' we can provide truly fundamental solutions to upstream innovation challenges in nuclear medicine, jointly empowering the technological upgrade of the global nuclear medicine industry.'.

这种战略协同是将我们由人工智能驱动的分子发现能力与领先的放射性药物工业化平台深度连接的关键一步。我们相信，通过“智能分子设计”和“精准放射性核素标记”双引擎驱动，能够为核医学上游创新挑战提供真正根本性的解决方案，共同赋能全球核医学产业的技术升级。

This strategic collaboration marks a solid step forward for Sanyou Bio in deepening industrial synergy and expanding into cutting-edge application areas. Starting from this partnership, both parties will continue to explore broader collaboration opportunities and strive to become a benchmark force driving upstream innovation in radiopharmaceutical development in China..

此次战略合作标志着三友生物在深化产业协同、拓展前沿应用领域方面迈出了坚实的一步。以此次合作为起点，双方将持续探索更广泛的合作机会，致力成为推动中国放射性药物研发上游创新的标杆力量。

About Sanyou

关于三友

Sanyou Biopharmaceuticals is a high-tech biopharmaceutical company driven by the mission of 'To make it easy to develop new drugs worldwide'. The company is committed to fundamentally addressing the key challenges at the source of innovative drug development.

三友生物制药是一家以“让全球新药研发更简单”为使命的高科技生物制药企业。公司致力于从源头上根本解决创新药物研发中的关键挑战。

Powered by its AI-STAL and supported by Sanyou AI-Drug Accelerator

由 AI-STAL 驱动，并由三友 AI 药物加速器支持

(SAI-DA),

（SAI-DA），

Sanyou provides one-stop comprehensive solutions to tackle all challenges in molecular generation and innovative drug R&D.

三友提供一站式综合解决方案，以应对分子生成和创新药物研发中的所有挑战。

Sanyou Bio has been dedicated to developing a world-class innovative biological drug R&D hub and to working collaboratively with partners worldwide to accelerate the development of innovative therapeutics.

三友生物致力于打造一个世界级的创新生物药物研发中心，并与全球合作伙伴携手合作，加速创新疗法的开发。

Headquartered in Shanghai, China, Sanyou has established global business centers across Asia, North America, and Europe, forming an international business network. The company currently operates and has planned over 20,000 square meters of R&D and GMP facilities.

三友总部设在中国上海，已在亚洲、北美和欧洲建立了全球业务中心，形成了国际化的业务网络。公司目前运营及规划中的研发和GMP设施面积超过20,000平方米。

Sanyou has established strong collaborations with more than 2,000 pharmaceutical and biotech companies worldwide, empowering over 1,200 new drug discovery and development projects. It has completed more than 50 collaboration projects, over 10 of which have advanced to IND approval and clinical development stages..

三友已与全球2000多家制药和生物技术公司建立了强有力的合作关系，赋能1200多个新药研发项目。已完成50多个合作项目，其中10多个已进入IND批准和临床开发阶段。

The company has filed over 170 invention patents, with more than 30 granted. It has also obtained over 10 national and international qualifications and system certifications, including National High-Tech Enterprise, Shanghai 'Specialized and Innovative' Enterprise, ISO9001, and ISO27001.

该公司已申请170余项发明专利，其中30余项已获得授权。此外，公司还获得了10多项国家和国际资质及体系认证，包括国家高新技术企业、上海市“专精特新”企业、ISO9001和ISO27001认证。

SOURCE Sanyou Bio

来源：三友生物

21

二十一

%

%

more press release views with

更多新闻稿浏览量，使用

Request a Demo

申请演示